Muhammet LİMON, Semral GÜLCEMAL, Fikret KANAT, Sema YILMAZ

Dirençli granülomatöz polianjiitis olgusu

Vaskülitler, kan damarlarının inflamatuvardestrüksiyonu ile karakterize heterojen bir grup hastalıktır. Vaskülitler tutulan damar özelliğine göre klinik bulgu verebilir. Primer vaskülitler damar tutulum özelliklerine göre büyük, orta ve küçük damar vasküliti olarak ayrılır. Granülomatöz polianjiitis(GPA) ANCA ilişkili küçük damar vaskülitidir. GPA sınırlı ve sistemik tutulumla seyredebilir. Bu olgu, akciğer tutulumu olan sistemik ve sınırlı GPA olgularında tedavive yan etkileri paylaşmak için sunulmuştur.

Vasculitis is a heterogeneous group of diseases characterized by inflammatory destruction of blood vessels. Vasculitis may result different clinical syndromes according to the characteristics of vasculitis. Vasculitides are separated as primers and secondary in the frequently used classification system, primer vasculitis is separated as small, mediıum and large vessel vasculitis according to its vascular involvement. Granulomatosis polyangitiis (GPA) is a small vessel vascülitis associated with ANCA. GPA may be seen with limited and systemic involvement. We presented this case to share treatment and side effects in cases of limited and systemic GPA.

PDF

___

Jenette JC, Folk RJ, Bacon K, et al. 2012 revised International ChapelHillConsensus Conference Nomenclature of vasculitides. Arthritis Rheum 2013; 65: 1-11.

Kallenberg CG. Antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Curr Opin Rheumatol 2007; 19.

Eriksson P, Jacobsson L, Lindell A, Nilsson JA, Skogh T. Improvedoutcome in Wegener’sgranulomatosisandmicroscopicpolyangiitis? A retrospectiveanalysis of 95 cases in twocohorts. J InternMed 2009; 265:496-506.

Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006; 368: 404-18.

Girard T, Mahr A, Noel LH, et al. Are antineutrophil cytoplasmic antibodies a marker predictive of relapse in Wegener’s granulomatosis? A prospectivestudy. Rheumatology (Oxford) 2001;40:147–51.

Stegeman CA. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis. Nephrol Dial Transplant 2002; 17: 2077–80.

Jayne D. Treatment of ANCA-associated systemic small vessel vasculitis. APMIS Suppl 2009; 127::3-9.

Puécha X, Pagnoux C, Perrodeau É, et al. Long-term outcomes among participants in the WEGENT trial of remission-maintenance therapy for granulomatosis with polyangiitis (Wegener’s) or microscopic polyangiitis. Arthritis Rheumatol 2016;68:690–701.

Carruthers D, Sherlock J. Evidence-based management of ANCA vasculitis. Best Pract Res Clin Rheumatol 2009; 23:367-78.

Jayne D. Review article: Progress of treatment in ANCA-associated vasculitis. Nephrology 2009;14:42-8.

Pallan L, Savage CO, Harper L. ANCA-associated vasculitis: from bench research to novel treatments. Nat Rev Nephrol 2009;5:278-86.

Specks U. Diffuse alveolar hemorrhage syndromes. Curr Opin Rheumatol 2001;13:12–7.

Kobayashi S, Inokuma S. Intrapulmonary hemorrhage in collagen-vascular diseases includes a spectrum of under lying conditions. Intern Med 2009;48:891-7.

Stone JH, Merkel PA, Spiera R, et al. RAVE-ITN research group, Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med2010:15;363:221.

Puéchal X.Targeted immunotherapy strategies in ANCA-associated vasculitis. Joint Bone Spine 2019;86:321-6.

Smith R, Jones R, Specks U, et al. Rituximab as re-induction therapy in relapsing ANCA-associated vasculitis [abstract]. Arthritis Rheumatol 2017;69:18.

Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener’s granulomatosis. NEngl J Med 2005,352:351.